(NASDAQ: EYPT) Eyepoint Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.06%.
Eyepoint Pharmaceuticals's revenue in 2024 is $46,018,000.On average, 4 Wall Street analysts forecast EYPT's revenue for 2024 to be $2,225,044,524, with the lowest EYPT revenue forecast at $1,544,754,552, and the highest EYPT revenue forecast at $2,740,693,560. On average, 2 Wall Street analysts forecast EYPT's revenue for 2025 to be $473,392,524, with the lowest EYPT revenue forecast at $149,492,376, and the highest EYPT revenue forecast at $797,292,672.
In 2026, EYPT is forecast to generate $240,682,725 in revenue, with the lowest revenue forecast at $149,492,376 and the highest revenue forecast at $331,873,075.